BOC-Val-Gly | 96433-92-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: BOC-Val-Gly
• 英文别名: 2-(2-{[(Tert-butoxy)carbonyl]amino}-3-methylbutanamido)acetic acid；2-[[3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]amino]acetic acid
• CAS: 96433-92-0
• 化学式: C₁₂H₂₂N₂O₅
• 分子量: 274.317
• InChiKey: BWPKSNMGVTYXQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  BOC-Val-Gly 在 ammonium iron(II) sulfate hexahydrate 、 氧气 、 二甲基吡啶胺 作用下， 以 乙腈 为溶剂， 以93 %的产率得到tert-butyl (1-formamido-3-methyl-1-oxobutan-2-yl)carbamate
  参考文献：
  名称：

  铁催化、光驱动脱羧氧化

  摘要：

  公开了铁催化、可见光诱导的羧酸脱羧氧化。该催化体系由天然存在的莫尔盐和容易获得的二(2-吡啶甲基)胺组成。有效地获得了一系列酮、醛和酰胺，包括市售的药物衍生物。基于化学计量实验和紫外-可见光监测提出了机械原理。

  DOI：

  10.1002/ejoc.202300892
• 作为产物：
  描述：

  N-[(1,1-二甲基乙氧基)羰基]-L-缬氨酰甘氨酸甲酯 在 盐酸 、 sodium hydroxide 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 以3.27 g (86%)的产率得到BOC-Val-Gly
  参考文献：
  名称：

  Cysteine proteinase inhibitor

  摘要：

  新的化合物是半胱氨酸蛋白酶抑制剂，其化学式为B - A - C，其中B = Pro-Arg-Leu-Val-Gly-，Arg-Leu-Val-Gly-，Leu-Val-Gly-或Val-Gly-，或零；N-末端氨基酸可以选择性地具有保护基团，A = 反应性基团，能够特异性地与游离-SH基团反应，C = -Gly-Pro-Met-Asp-Ala；-Gly-Pro-Met-Asp；-Gly-Pro-Met；或-Gly-Pro，或零；但是B和C不能同时为零。

  公开号：

  US05037957A1

文献信息

• PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
  申请人：CHEMOCENTRYX, INC.

  公开号：US20190300526A1

  公开（公告）日：2019-10-03

  The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

  本公开提供了化合物IA、IB、IC、IIA、IIB和IIC的结构，或其在药学上可接受的盐，这些化合物是C5a受体的调节剂。还提供了包括治疗涉及C5a病理性激活的疾病或疾病的药物组合物和使用方法，以及非药物应用。
• [EN] PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS<br/>[FR] PROMÉDICAMENTS D'UN INHIBITEUR DE CDK POUR LE TRAITEMENT DE CANCERS
  申请人：RISEN SUZHOU PHARMA TECH CO LTD

  公开号：WO2020215156A1

  公开（公告）日：2020-10-29

  There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers. (I)

  提供了I式化合物，以及其药用盐和酯，以及用于抑制或调节细胞周期依赖性激酶（CDK）和/或糖原合成酶-3（GSK-3）活性的药物组合物，用于治疗由细胞周期依赖性激酶和/或糖原合成酶-3介导的疾病状态或病况，包括癌症。
• Electrochemical Dimethyl <scp>Sulfide‐Mediated</scp> Esterification of Amino Acids
  作者：Yongli Li、Huamin Wang、Heng Zhang、Aiwen Lei

  DOI：10.1002/cjoc.202100395

  日期：2021.11

  for esterification of amino acids has been reported. A series of amino acids could react smoothly with alcohols, affording the desired esterification products with good efficiency. Importantly, the tolerance of peptides and gram-scale synthesis shed light on the utility of this protocol. Mechanistically, the dimethyl sulfide as a mediator plays an essential role in the transformation of amino acids

  已经报道了用于氨基酸酯化的二甲基硫醚介导的电化学合成策略。一系列氨基酸可以与醇类顺利反应，高效地提供所需的酯化产物。重要的是，肽的耐受性和克级合成阐明了该协议的实用性。从机制上讲，二甲基硫醚作为介体在氨基酸的转化中起着至关重要的作用。
• RILUZOLE PRODRUGS AND THEIR USE
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：US20180036290A1

  公开（公告）日：2018-02-08

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的制药组合物包括替代利鲁唑前药，通过释放利鲁唑治疗包括黑色素瘤、乳腺癌、脑癌和前列腺癌等癌症。利鲁唑的前药具有增强的肝代谢稳定性，并通过口服途径输送到全身循环中，然后通过酶促或一般的生物物理释放过程在血浆中裂解释放利鲁唑。
• 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES
  申请人：Dennis Edward A.

  公开号：US20120095096A1

  公开（公告）日：2012-04-19

  The disclosure provides a series of 2-oxoamides based on dipeptides and pseudodipeptides, which were synthesized and their activities toward two human intracellular phospholipases A2 (GIVA CPLA 2 and GVIA 1PLA 2 ) and one human secretory phospholipase A2 (GVsPLA 2 ) were evaluated. Derivatives containing a free carboxyl group are selective GIVA cPLA 2 inhibitors. A derivative based on the ethyl ester of an ether pseudodipeptide is the first 2-oxoamide, which preferentially inhibits GVIA iPLA 2 . The effect of 2-oxoamides on the generation of arachidonic acid from RAW 264.7 macrophages was also studied. It was found that selective GIVA cPLA 2 inhibitors preferentially inhibited cellular arachidonic acid release; in which one pseudodipeptide gave an IC50 value of 2 μM.

  该披露提供了一系列基于二肽和假二肽的2-氧代酰胺，这些化合物已被合成，并评估了它们对两种人类细胞内磷脂酶A2（GIVA CPLA2和GVIA 1PLA2）以及一种人类分泌型磷脂酶A2（GVsPLA2）的活性。含有自由羧基的衍生物是选择性的GIVA CPLa href=https://www.molaid.com/MS_77825 target="_blank">LA2抑制剂。一种基于乙酰化假二肽的2-氧代酰胺是首个优先抑制GVIA iPLA2的化合物。还研究了2-氧代酰胺对RAW 264.7巨噬细胞中花生四烯酸生成的影响。发现选择性的GIVA CPLa href=https://www.molaid.com/MS_77825 target="_blank">LA2抑制剂优先抑制细胞花生四烯酸释放；其中一个假二肽给出了2μM的IC50值。